Design, Synthesis, and Biological Evaluation of New Selective PDE4 Inhibitors for Topical Treatment of Psoriasis

Psoriasis is a complex and chronic inflammatory disease. Current drugs help control the symptoms of psoriasis but make no cure, urging discovery of novel drugs. We report in this paper the discovery of new phosphodiesterase 4 (PDE4) inhibitors for treatment of psoriasis. We designed and synthesized 45 new compounds, among which <b>14h</b> exhibited IC<sub>50</sub> of 0.57 nM for PDE4D and >4100-fold selectivity over other PDE families. Compound <b>14h</b> inhibited release of inflammatory cytokines of TNF-α (IC<sub>50</sub> = 34.2 μM) and IL-6 (IC<sub>50</sub> = 40.9 μM) in Raw264.7 cells and reduced the expression of IL-1β and IL-17A in the skin of psoriasis mice. In addition, <b>14h</b> alleviated IMQ-induced psoriasis in the mouse model and reduced the erythema level, scales, and thickness of the back skin of the mice. In short, our results suggested that PDE4 inhibitor <b>14h</b> is a strong candidate for the topical treatment of psoriasis.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2024-11-13
DOI
https://doi.org/10.1021/acs.jmedchem.4c01804
Citations
5
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
1.20

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Design, Synthesis, and Biological Evaluation of New Selective PDE4 Inhibitors for Topical Treatment of Psoriasis

Hengming Ke, Wei Pan, Yanghui Ou, Dengqin He et al.
5 citations
Journal of Medicinal Chemistry
Psoriasis: Treatment and Pathogenesis
1.20
article

Design, Synthesis, and Biological Evaluation of New Selective PDE4 Inhibitors for Topical Treatment of Psoriasis

Hengming Ke, Wei Pan, Yanghui Ou, Dengqin He, Jia‐Qiang Wu, Xudong Qian, Jiaxin Chen, Dandan Chen, Liu Y, Mengjie Li, Guoping Zhang, Zichen Xu, Hongliang Yao, Yan Geng, Jun Wang, Gang Li
article en
5 citations

Abstract

Psoriasis is a complex and chronic inflammatory disease. Current drugs help control the symptoms of psoriasis but make no cure, urging discovery of novel drugs. We report in this paper the discovery of new phosphodiesterase 4 (PDE4) inhibitors for treatment of psoriasis. We designed and synthesized 45 new compounds, among which <b>14h</b> exhibited IC<sub>50</sub> of 0.57 nM for PDE4D and >4100-fold selectivity over other PDE families. Compound <b>14h</b> inhibited release of inflammatory cytokines of TNF-α (IC<sub>50</sub> = 34.2 μM) and IL-6 (IC<sub>50</sub> = 40.9 μM) in Raw264.7 cells and reduced the expression of IL-1β and IL-17A in the skin of psoriasis mice. In addition, <b>14h</b> alleviated IMQ-induced psoriasis in the mouse model and reduced the erythema level, scales, and thickness of the back skin of the mice. In short, our results suggested that PDE4 inhibitor <b>14h</b> is a strong candidate for the topical treatment of psoriasis.

Journal of Medicinal ChemistryVol. 67(22)
University of North Carolina at Chapel Hill (US), Jinan University (CN), Guangdong Academy of Sciences (CN), Institute of Zoology (CN), Wuyi University (CN)
Guangdong Academy of Sciences, Special Project for Research and Development in Key areas of Guangdong Province, Basic and Applied Basic Research Foundation of Guangdong Province
Openalex Percentile: Top 20%
Psoriasis: Treatment and Pathogenesis
1.20
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.